<DOC>
	<DOCNO>NCT00254800</DOCNO>
	<brief_summary>The purpose study examine effect take exenatide blood level ( pharmacokinetics ) orally-administered contraceptive .</brief_summary>
	<brief_title>The Effects Exenatide Oral Contraceptive Pharmacokinetics Healthy Females</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Premenopausal female childbearing potential . Body Mass Index ( BMI ) 19 35 kg/m^2 , inclusive . On implanted contraceptive 6 month , injectable contraceptive 12 month prior study . Evidence diabetes mellitus . Participation study involve administration investigational compound within past 3 month .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exenatide</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>